We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Diagnostic Value of Serum CHI3L1 in Hepatocellular Carcinoma Explored

By LabMedica International staff writers
Posted on 02 Feb 2022
Primary liver cancer is the sixth diagnosed cancer and the fourth cause of cancer-related death worldwide. Hepatocellular carcinoma (HCC) is the major pathological category and comprises a 75%–85% incidence of primary liver cancer cases.

Chitinase 3-like protein 1 (CHI3L1) belongs to the family 18-glycosyl hydrolase but lacks chitinolytic activity. CHI3L1 has shown better performance in diagnosing liver fibrosis than other noninvasive methods in chronic hepatitis B patients.

Scientists specializing in Hepatology at the University of Chinese Academy of Sciences (Ningbo, China) enrolled in a retrospective study the following: matched age and gender subjects, 40 patients with liver cirrhosis, 40 patients with chronic hepatitis, and 40 healthy subjects were enrolled in the control group. The data was collected from December 2018 to April 2020. The serum CHI3L1 level was determined by enzyme-linked immunosorbent assay (ELISA) and in a blinded manner.

The CHI3L1 ELISA Kit was produced by Proprium Biotech Company Limited, (Hangzhou, China). The expression level of CHI3L1 was detected once the subjects first visit the clinic or admit to hospital. The follow-up time was 8 to 22 months. During the follow-up period, laboratory monitoring was performed every 3 to 6 months, including routine blood chemistry tests and imaging studies using computed tomography (CT) or magnetic resonance imaging (MRI) to monitor disease status. The clinicopathological data of 50 paired HCC and adjacent non-tumor tissues as well as 278 unpaired HCC tissues, and the relative expression levels of CHI3L1 was studied.

The investigators reported that the median serum level of CHI3L1 in the HCC group was 168.84 ng/mL (95%CI = 96.24, 322.61 ng/mL), which was significantly higher than the median serum level of CHI3L1 in the control group, median = 71.36 ng/mL (95% CI = 48.63, 114.77 ng/mL). Serum CHI3L1 level was closely correlated with serum α-fetoprotein (AFP) level, tumor-node-metastasis (TNM) stage, Child-Pugh stage, the maximum diameter of tumor, and presence of liver cirrhosis, but there was no significant correlation between gender and age.

The patients with high AFP level (>400 ng/L), TNM III + IV stage, large tumor diameter, liver cirrhosis, and Child-Pugh B + C had higher serum CHI3L1 levels. The overall survival (OS) rate of patients with high expression of CHI3L1 was significantly lower than that of patients with low expression of CHI3L1. Combining the serum CHI3L1 and α-fetoprotein (AFP) by a binary logistic regression model can increase the diagnostic sensitivity to 97.5%. Multivariate Cox regression analysis indicated that CHI3L1 is an independent prognostic factor in patients with HCC.

The authors concluded that they compared the difference of serum CHI3L1 between the HCC group and the control group, analyzed the diagnostic performance of CHI3L1 for HCC, and evaluated the prognostic power of serum CHI3L1 in HCC patients. The results showed that serum CHI3L1 can help to increase diagnostic power and evaluate prognosis for HCC patients. The study was published on January 16, 2022 in the Journal of Clinical Laboratory Analysis.

Related Links:
University of Chinese Academy of Sciences
Proprium Biotech Company Limited



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.